The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Abstract
Patients with recurrent gliomas (n = 14) were treated with bevacizumab and carboplatin, cpt-11, or etoposide. Follow-up MRI scans were obtained 2 to 6 weeks after initiation of treatment. Contrast-enhancing tumor shrank in 7 patients, with reductions evident in as little as 2 weeks after initiation of therapy. Treatment seemed more effective for heterogeneously enhancing tumor compared with solidly enhancing tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. W. (1996) · PubMed · Cited by 1,727
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
MR imaging correlates of survival in patients with high-grade gliomas.
Pope, W. B., Sayre, J. W., Perlina, A., Villablanca, J. P., Mischel, P. S., & Cloughesy, T. F. (2005) · PubMed Central · Cited by 418
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
de Wit, M. C. Y., de Bruin, H. G., Eijkenboom, W., Sillevis Smitt, P. A. E., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 357
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
Box, P. (2005) · Dkgest of the World Latest Medical Information · Cited by 299
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P., & Cloughesy, T. F. (2006) · Neurology · doi:10.1212/01.wnl.0000208958.29600.87 · Cited by 271
Prados, M. D., Lamborn, K., Yung, W. K. A., Jaeckle, K., Robins, H. I., Mehta, M., Fine, H. A., Wen, P. Y., Cloughesy, T., Chang, S., et al. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-010 · Cited by 254
Masi, A., Becchetti, A., Cassulini, R. R., Polvani, S., Hofmann, G., Buccoliero, A. M., Paglierani, M., Pollo, B., Taddei, G. L., Gallina, P., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602775 · Cited by 154
Jordan, B. F., Runquist, M. L., Raghunand, N., Baker, A. F., Williams, R. R., Kirkpatrick, L., Powis, G., & Gillies, R. J. (2005) · Neoplasia · doi:10.1593/neo.04628 · Cited by 138
Cited by
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 801
Metadata
- Authors
- Chamberlain, M. C.
- Venue
- Neurology
- Published
- 2006-12-12
- Volume
- 67
- Issue
- 11
- Pages
- 2089-2089
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2095027624
- Cited by
- 264
- References
- 12
- FWCI
- 14.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. https://app.cochat.ai/papers/10.1212/01.wnl.0000250628.10420.d8
- The paper
- Chamberlain, M. C. (2006). MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. https://doi.org/10.1212/01.wnl.0000250628.10420.d8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.